Debra Gase
Nurse Practitioner · Saint Louis, MONPI 1972529105
Payments from drug & device makers
What this record shows
This record is dominated by education: $9,399 of the $11,306 with a category attached, or 83.1%. Insmed, Inc. accounts for 80.1% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2021 at $9,679 and has fallen 97.7% since, to $227 in 2025. Among nurse practitioner clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 214 payments — averaging $52.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Insmed, Inc.$9K
- Viiv Healthcare Company$780
- AbbVie$368
- Astellas Pharma US Inc$350
- Merck$345
- Gilead$154
- plus $248 from 4 others
What the payments were for
- Food & beverage$1,90717%
- Education$9,39983%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Insmed, Inc. | 111 | $9,061 |
| Viiv Healthcare Company | 43 | $780 |
| AbbVie | 16 | $368 |
| Astellas Pharma US Inc | 5 | $350 |
| Merck | 17 | $345 |
| Gilead | 9 | $154 |
| Mayne Pharma Commercial LLC | 4 | $81 |
| Johnson & Johnson | 4 | $76 |
| Paratek Pharmaceuticals, Inc. | 4 | $74 |
| Phathom Pharmaceuticals, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,306 in reported general payments places this provider in the 95th percentile of 1,898 nurse practitioner providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 732 | $2,898,774 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 269 | $1,103,640 |
| TivicayDolutegravir Sodium | 275 | $708,827 |
| JulucaDolutegravir/Rilpivirine | 163 | $587,655 |
| CabenuvaCabotegravir/Rilpivirine | 66 | $430,058 |
| DescovyEmtricitabine/Tenofov Alafenam | 176 | $416,459 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 113 | $413,316 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 82 | $371,171 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 85 | $341,913 |
| PrezcobixDarunavir/Cobicistat | 60 | $154,052 |
| RukobiaFostemsavir Tromethamine | 13 | $121,561 |
| Darunavir | 95 | $104,222 |
| PifeltroDoravirine | 56 | $103,904 |
| DelstrigoDoravirine/Lamivu/Tenofov Diso | 40 | $103,875 |
| CresembaIsavuconazonium Sulfate | 14 | $91,950 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Genvoya, Descovy, Truvada | $154 | $4,440,6231,189 claims |
| Viiv Healthcare CompanyTivicay, Juluca, Cabenuva, Triumeq, Rukobia | $780 | $2,234,111615 claims |
| Johnson & JohnsonPrezcobix, Complera, Xarelto | $76 | $241,73595 claims |
| MerckPifeltro, Delstrigo, Dulera, Januvia | $345 | $227,684148 claims |
| Astellas Pharma US IncCresemba | $350 | $91,95014 claims |
| AbbVieNorvir | $368 | $3,03312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,898 nurse practitioner providers in Missouri.
Other nurse practitioner in Saint Louis
- Carrie Roth BettlachSaint Louis$21K
- Lisa CampbellSaint Louis$16K
- Angela VickroySaint Louis$15K
- Isabel HartigSaint Louis$13K
- Kathryn LindsaySaint Louis$13K
- Leanna ScheidemantelSaint Louis$12K
- Samra FajicSaint Louis$12K
- Kristin DalySaint Louis$11K
- Kimbra CardwellSaint Louis$11K
- Jamie GriffithSaint Louis$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.